Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Boehringer Ingelheim
Harvard Business School
McKinsey

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR TRILIPIX


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Trilipix

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00300430 ↗ Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Completed Abbott Phase 3 2006-09-01 The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
NCT00639158 ↗ Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood Completed Abbott Phase 3 2008-02-01 The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.
NCT00813527 ↗ Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels Completed Takeda Phase 2 2006-02-01 The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
NCT00839293 ↗ Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules Completed Abbott Phase 1 2009-02-01 The purpose of this study is to evaluate the safety and compare the bioavailability of fenofibric acid from 2 different dosage strengths of ABT-335.
NCT01025492 ↗ Study of Trilipix Effects on Lipids and Arteries Terminated Abbott Phase 4 2009-11-01 Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance.
NCT01025492 ↗ Study of Trilipix Effects on Lipids and Arteries Terminated University of Utah Phase 4 2009-11-01 Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance.
NCT01030328 ↗ AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis Terminated Piedmont Healthcare Phase 3 2009-11-01 This study will examine how an approved drug (TriLipix), when used in combination with a statin (a drug that lowers blood cholesterol levels), affects the makeup of plaque. Patients will be randomly assigned to receive either the study treatment (TriLipix plus Atorvastatin) or the comparison treatment (a placebo). Comparison of the effect on the makeup of plaque will be done by using coronary artery computed tomography angiography (CTA), which all participants will have at enrollment and at the end of the study (18 months after enrollment).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trilipix

Condition Name

Condition Name for Trilipix
Intervention Trials
Dyslipidemia 2
Healthy 2
Mixed Dyslipidemia 2
Coronary Heart Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trilipix
Intervention Trials
Myocardial Ischemia 3
Dyslipidemias 3
Coronary Artery Disease 3
Heart Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trilipix

Trials by Country

Trials by Country for Trilipix
Location Trials
United States 61
Canada 2
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trilipix
Location Trials
Illinois 4
California 3
South Carolina 3
Georgia 3
Arizona 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trilipix

Clinical Trial Phase

Clinical Trial Phase for Trilipix
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trilipix
Clinical Trial Phase Trials
Completed 7
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trilipix

Sponsor Name

Sponsor Name for Trilipix
Sponsor Trials
Abbott 4
Piedmont Healthcare 1
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trilipix
Sponsor Trials
Industry 6
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Dow
Boehringer Ingelheim
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.